- Home
- RDCM vs BDTX Comparison
RDCM vs BDTX Comparison
Compare RDCM & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDCM
- BDTX
- Stock Information
- Founded
- RDCM 1985
- BDTX 2014
- Country
- RDCM Israel
- BDTX United States
- Employees
- RDCM N/A
- BDTX N/A
- Industry
- RDCM Computer peripheral equipment
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RDCM Technology
- BDTX Health Care
- Exchange
- RDCM Nasdaq
- BDTX Nasdaq
- Market Cap
- RDCM 203.7M
- BDTX 181.4M
- IPO Year
- RDCM 1997
- BDTX 2020
- Fundamental
- Price
- RDCM $13.71
- BDTX $3.90
- Analyst Decision
- RDCM Strong Buy
- BDTX Strong Buy
- Analyst Count
- RDCM 1
- BDTX 5
- Target Price
- RDCM $18.00
- BDTX $12.00
- AVG Volume (30 Days)
- RDCM 53.8K
- BDTX 1.0M
- Earning Date
- RDCM 11-12-2025
- BDTX 11-04-2025
- Dividend Yield
- RDCM N/A
- BDTX N/A
- EPS Growth
- RDCM 79.61
- BDTX N/A
- EPS
- RDCM 0.56
- BDTX 0.25
- Revenue
- RDCM $66,334,000.00
- BDTX $70,000,000.00
- Revenue This Year
- RDCM $18.07
- BDTX N/A
- Revenue Next Year
- RDCM $11.52
- BDTX N/A
- P/E Ratio
- RDCM $25.42
- BDTX $15.62
- Revenue Growth
- RDCM 18.18
- BDTX N/A
- 52 Week Low
- RDCM $9.81
- BDTX $1.20
- 52 Week High
- RDCM $15.98
- BDTX $4.03
- Technical
- Relative Strength Index (RSI)
- RDCM 48.29
- BDTX 68.52
- Support Level
- RDCM $13.76
- BDTX $3.62
- Resistance Level
- RDCM $14.32
- BDTX $4.03
- Average True Range (ATR)
- RDCM 0.49
- BDTX 0.21
- MACD
- RDCM -0.09
- BDTX 0.05
- Stochastic Oscillator
- RDCM 14.19
- BDTX 86.63
About RDCM Radcom Ltd.
Radcom Ltd Ltd is engaged in providing network intelligence, 5G ready cloud-native, network intelligence solutions for telecom operators transitioning to 5G. The company has a network intelligence solution for 5G namely Radcom ACE. Its products consist of Radcom Network Visibility, Radcom Service Assurance, and Radcom Network Insights. It has offices in Israel, the United States, Brazil, and India. Key revenue is derived from sales in North America.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.